iiinova — where your digital self keeps evolving

Reposted by Dr Colin Lindsay

Elizabeth McKenna @elizsmckenna.bsky.social · 24/06/2026

Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer - by William McDaid, Helen Adderley, @drcolinlindsay.bsky.social, and colleagues doi.org/10.1158/2159... @cruk-mi.bsky.social @officialuom.bsky.social

121

Reposted by Dr Colin Lindsay

BTOG @btog.bsky.social · 17/09/2025

New Podcast Alert! BTOG does … Neo-adjuvant / peri-operative chemoimmunotherapy @tnewsomdavis.bsky.social & Emma O'Dowd talk to Jason Adhikaree. Subscribe via Apple App Store, Spotify or Amazon Music – just search BTOG or listen via the BTOG website. www.btog.org/btog-podcasts/ #LCSM #lungcancer

052

Reposted by Dr Colin Lindsay

Becki Lee @beckilee.bsky.social · 22/08/2025

The Lee lab is expanding! We are really interested in mechanisms of local and systemic immune tolerance particularly in liver metastases - X2 research technicians 💡 Creative fun environment 🌱 Opportunities to grow 🫂 Highly collaborative with clinical+basic research 📢 Please spread word!

jobs.manchester.ac.uk

Research Technician:Oxford Road

175

Dr Colin Lindsay @drcolinlindsay.bsky.social · 18/04/2025

It is a good Friday. Walking from Kelvingrove Art Gallery and Park along the River Kelvin to the Botanics in Glasgow's West End. Finish at Byres Road. Not done in a while and probably my favourite thing to do in the UK. Strong smell of wild garlic today.

390

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

3) KROCUS single arm phase 2 showing magnificent activity with fulverasib + cetuximab in 1st line nsclc, pdl1 agnostic. Very important and unexpected non IO option. It feels like egfr antibodies maybe offering something different to TKIs here. Again congrats+++ to all investigators #ELCC25

031

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

043

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

065

Dr Colin Lindsay @drcolinlindsay.bsky.social · 27/03/2025

Outstanding RAS targeting presentations just passed at #ELCC25 I'm a little bit blown away...

010

Dr Colin Lindsay @drcolinlindsay.bsky.social · 04/03/2025

Our excellent LCNEC project manager, Karen Shackcloth, presenting her poster yesterday at #BTOG2025 Her dedication to this role has been critical for our SIG efforts towards moving towards standardised diagnostic and management LCNEC pathways

031

Dr Colin Lindsay @drcolinlindsay.bsky.social · 04/03/2025

Here is the wonderful Dr Ana Parreira presenting her poster on KRASm radiotherapy outcomes at #BTOG2025 Ana is a Portuguese medical oncologist bridging the clin med oncology divide with unrelenting diplomacy and discipline! @mcrcnews.bsky.social

082

Reposted by Dr Colin Lindsay

Sanjay Popat @drsanjaypopat.bsky.social · 02/03/2025

En route to #BTOG25? The team are ready! Looking forward to seeing you there. Do say “hello” when you catch me! It will be an awesome meeting! @btog.bsky.social

194

Reposted by Dr Colin Lindsay

Natalie Cook @oncocook.bsky.social · 28/02/2025

Lovely night with our @uom-dcs.bsky.social Medical Oncology clinical academic trainees (ACFs/ACLs) who are thankfully growing in number. With @drcolinlindsay.bsky.social. Great to see everyone! @mcrcnews.bsky.social

061

Dr Colin Lindsay @drcolinlindsay.bsky.social · 15/02/2025

Amazing speakers, location, hospitality. Make sure you come if interested in RAS precision medicine!

021

Dr Colin Lindsay @drcolinlindsay.bsky.social · 15/01/2025

We had a fantastic end to 2024 in the Manchester RAS lab www.mcrc.manchester.ac.uk/research/dis... Our 1st PhD student passed his viva...George Morrissey is now beginning med onc training and is destined for great things. @official-uom.bsky.social @cruk-mi.bsky.social

262